Swedbank
BMRN icon

Swedbank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Swedbank’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.2M Buy
1,314,787
+522,600
+66% +$28.6M 0.06% 201
2026
Q1 		$44.8M Sell
792,187
-4,550
-0.6% -$265K 0.05% 238
2025
Q4 		$47.4M Buy
796,737
+329,794
+71% +$18M 0.05% 232
2025
Q3 		$25.3M Buy
466,943
+35,000
+8% +$2M 0.03% 344
2025
Q2 		$23.7M Buy
431,943
+2,100
+0.5% +$124K 0.03% 333
2025
Q1 		$30.4M Sell
429,843
-2,279
-0.5% -$153K 0.04% 282
2024
Q4 		$28.4M Buy
432,122
+43,593
+11% +$2.92M 0.03% 289
2024
Q3 		$27.3M Buy
388,529
+100,000
+35% +$8.36M 0.03% 286
2024
Q2 		$23.8M Sell
288,529
-7,600
-3% -$633K 0.03% 290
2024
Q1 		$25.9M Sell
296,129
-170,100
-36% -$15.2M 0.04% 280
2023
Q4 		$45M Sell
466,229
-40,800
-8% -$3.61M 0.07% 194
2023
Q3 		$44.9M Hold
507,029
– – 0.08% 185
2023
Q2 		$43.9M Hold
507,029
– – 0.07% 200
2023
Q1 		$49.3M Buy
507,029
+59,200
+13% +$6.14M 0.1% 173
2022
Q4 		$46.3M Buy
447,829
+26,900
+6% +$2.53M 0.1% 185
2022
Q3 		$35.7M Sell
420,929
-108,190
-20% -$9.63M 0.08% 198
2022
Q2 		$43.8M Buy
529,119
+24,661
+5% +$1.96M 0.1% 182
2022
Q1 		$38.9M Buy
504,458
+183,493
+57% +$15.4M 0.07% 226
2021
Q4 		$28.6M Sell
320,965
-15,058
-4% -$1.24M 0.05% 278
2021
Q3 		$26M Buy
336,023
+192,144
+134% +$15.2M 0.05% 289
2021
Q2 		$12M Hold
143,879
– – 0.02% 446
2021
Q1 		$10.9M Buy
+143,879
New +$11.8M 0.02% 451

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Swedbank's BMRN Position: Q2 2026 in Review

Swedbank increased its BioMarin Pharmaceuticals (BMRN) stake by 66% in Q2 2026, buying an estimated $28.6M and bringing the position to 1,314,787 shares worth $75.2M. The position accounts for 0.06% of the portfolio, ranked #201.

Swedbank first reported a position in BMRN in Q1 2021 and has held it in 22 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Swedbank held 1,314,787 shares of BioMarin Pharmaceuticals worth $75.2M as of Q2 2026.
  • Swedbank bought 522,600 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $28.6M.
  • BioMarin Pharmaceuticals made up 0.06% of Swedbank's portfolio in Q2 2026, its #201 holding.
  • Swedbank first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Swedbank's 13F filing for Q2 2026, filed 15 Jul 2026.